Author
By Adithi Iyer In February, the news broke that the Food and Drug Administration (FDA) had approved a “first of its kind” new cancer therapy. Iovance’s AMTAGVITM, the subject of the approval, is a personalized…
Does organoid intelligence warrant recognition for the work it produces? And is that output protectible?
Organoids purport to tell us a great deal about the human body. Here are some legal questions to consider as the technology is widely adopted in R&D — and beyond.
A rundown of the major legal questions at play in the New York Times-OpenAI lawsuit.
The property law approach to ownership does not draw hard lines with respect to biological materials like tissue.
Biden’s Executive Order on artificial intelligence is an important development for health care practitioners, researchers, and legal experts.
The privatization of next-generation medical technologies, especially in regenerative and precision medicine, further muddies the data-protection waters.
Could a corporate, direct-to-consumer cell-based testing service be the next 23andme? And what would that mean for patients?
